科创板第五套上市标准重启后，首家适用企业IPO申请获受理

Core Insights - The IPO application of Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has been accepted, marking it as the first company to be accepted under the restarted fifth listing standard of the Sci-Tech Innovation Board [1] - The company aims to raise 1.5 billion yuan through its IPO [1] - Tainuo Maibo has been recognized as a company focused on innovative biopharmaceutical development, with a significant emphasis on long-term R&D projects [2] Financial Performance - The company's revenue from 2022 to Q1 2025 is reported as 4.34 million yuan, 0 yuan, 15.06 million yuan, and 169,300 yuan respectively [1] - The net losses during the same period are 429 million yuan, 446 million yuan, 515 million yuan, and 177 million yuan respectively [1] Investment and Partnerships - Tainuo Maibo has received investment from Zhuhai Hillhouse Private Equity Fund Management Co., Ltd., which is recognized as a qualified institutional investor [2] - Hillhouse Capital, the parent company of Zhuhai Hillhouse, has a track record of investing in over five technology companies that have listed on the Sci-Tech Innovation Board in the past five years [2] Regulatory Framework - The acceptance of Tainuo Maibo's IPO is part of the implementation of new policies aimed at enhancing the inclusivity of the Sci-Tech Innovation Board for high-quality, unprofitable technology companies [1] - The new policies include the establishment of a growth tier and the introduction of qualified institutional investors [1][3]